Data from FDA - Curated by EPG Health - Last updated 24 July 2018

Indication(s)

1 INDICATIONS AND USAGE OZURDEX ® is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) (1.1) The treatment of non-infectious uveitis affecting the posterior segment of the eye (1.2) The treatment of diabetic macular edema (1.3) 1.1 Retinal Vein Occlusion OZURDEX ® (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). 1.2 Posterior Segment Uveitis OZURDEX ® is indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye. 1.3 Diabetic Macular Edema OZURDEX ® is indicated for the treatment of diabetic macular edema.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Sleep Apnea

Sleep Apnea

Sleep apnea is a chronic condition characterised by recurrent interruptions in breathing throughout the sleep cycle. Learn about the two main types of sleep apnea and hear from experts as they present the latest research at the Sleep and Breathing conference (Marseille, 2019).

Cardiovascular Metabolism Knowledge Centre

Cardiovascular Metabolism Knowledge Centre

The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Load more

Related Content

Advisory information

contraindications
4 CONTRAINDICATIONS Ocular or periocular infections (4.1) Glaucoma (4.2) Torn or ruptured posterior lens capsule (4.3) Hypersensitivity (4.4) 4.1 Ocular or Periocular Infections OZURDEX ® (dexamethasone intravitreal implant) is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases. 4.2 Glaucoma OZURDEX ® is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8. 4.3 Torn or Ruptured Posterior Lens Capsule OZURDEX ® is contraindicated in patients whose posterior lens capsule is torn or ruptured because of the risk of migration into the anterior chamber. Laser posterior capsulotomy in pseudophakic patients is not a contraindication for OZURDEX ® use. 4. 4 Hypersensitivity OZURDEX ® is contraindicated in patients with known hypersensitivity to any components of this product [see Adverse Reactions ( 6 )].
Adverse reactions
6 ADVERSE REACTIONS In controlled studies, the most common adverse reactions reported by 20–70% of patients were cataract, increased intraocular pressure and conjunctival hemorrhage. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Figure 1: Mean IOP during the study 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adverse reactions associated with ophthalmic steroids including OZURDEX ® include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera. Retinal Vein Occlusion and Posterior Segment Uveitis The following information is based on the combined clinical trial results from 3 initial, randomized, 6-month, sham-controlled studies (2 for retinal vein occlusion and 1 for posterior segment uveitis): Table 1: Adverse Reactions Reported by Greater than 2% of Patients MedDRA Term OZURDEX ® N=497 (%) Sham N=498 (%) Intraocular pressure increased 125 (25%) 10 (2%) Conjunctival hemorrhage 108 (22%) 79 (16%) Eye pain 40 (8%) 26 (5%) Conjunctival hyperemia 33 (7%) 27 (5%) Ocular hypertension 23 (5%) 3 (1%) Cataract 24 (5%) 10 (2%) Vitreous detachment 12 (2%) 8 (2%) Headache 19 (4%) 12 (2%) Increased IOP with OZURDEX ® peaked at approximately week 8. During the initial treatment period, 1% (3/421) of the patients who received OZURDEX ® required surgical procedures for management of elevated IOP. Following a second injection of OZURDEX ® in cases where a second injection was indicated, the overall incidence of cataracts was higher after 1 year. In a 2 year observational study, among patients who received >2 injections, the most frequent adverse reaction was cataract 54% (n= 96 out of 178 phakic eyes at baseline). Other frequent adverse reactions from the 283 treated eyes, regardless of lens status at baseline, were increased IOP 24% (n = 68) and vitreous hemorrhage 6.0% (n = 17). Diabetic Macular Edema The following information is based on the combined clinical trial results from 2 randomized, 3-year, sham-controlled studies in patients with diabetic macular edema. Discontinuation rates due to the adverse reactions listed in Table 2 were 3% in the OZURDEX ® group and 1% in the Sham group. The most common ocular (study eye) and non-ocular adverse reactions are shown in Tables 2 and 3: Table 2: Ocular Adverse Reactions Reported by ≥ 1% of Patients and Non-ocular Adverse Reactions Reported by ≥ 5% of Patients MedDRA Term OZURDEX ® N=324 (%) Sham N=328 (%) Ocular Cataract1 166/2432 (68%) 49/230 (21%) Conjunctival hemorrhage 73 (23%) 44 (13%) Visual acuity reduced 28 (9%) 13 (4%) Conjunctivitis 19 (6%) 8 (2%) Vitreous floaters 16 (5%) 6 (2%) Conjunctival edema 15 (5%) 4 (1%) Dry eye 15 (5%) 7 (2%) Vitreous detachment 14 (4%) 8 (2%) Vitreous opacities 11 (3%) 3 (1%) Retinal aneurysm 10 (3%) 5 (2%) Foreign body sensation 7 (2%) 4 (1%) Corneal erosion 7 (2%) 3 (1%) Keratitis 6 (2%) 3 (1%) Anterior Chamber Inflammation 6 (2%) 0 (0%) Retinal tear 5 (2%) 2 (1%) Eyelid ptosis 5 (2%) 2 (1%) Non-ocular Hypertension 41 (13%) 21 (6%) Bronchitis 15 (5%) 8 (2%) 1 Includes cataract, cataract nuclear, cataract subcapsular, lenticular opacities in patients who were phakic at baseline. Among these patients, 61% of OZURDEX ® subjects vs. 8% of sham-controlled subjects underwent cataract surgery. 2 243 of the 324 OZURDEX ® subjects were phakic at baseline; 230 of 328 sham-controlled subjects were phakic at baseline. Increased Intraocular Pressure Table 3: Summary of Elevated Intraocular Pressure (IOP) Related Adverse Reactions IOP Treatment: N (%) OZURDEX ® N=324 Sham N=328 IOP elevation ≥10 mm Hg from Baseline at any visit 91 (28%) 13 (4%) ≥30 mm Hg IOP at any visit 50 (15%) 5 (2%) Any IOP lowering medication 136 (42%) 32 (10%) Any surgical intervention for elevated IOP * 4 (1.2%) 1 (0.3%) * OZURDEX ®: 1 surgical trabeculectomy for steroid-induced IOP increase, 1 surgical trabeculectomy for iris neovascularization, 1 laser iridotomy, 1 surgical iridectomy Sham: 1 laser iridotomy The increase in mean IOP was seen with each treatment cycle, and the mean IOP generally returned to baseline between treatment cycles (at the end of the 6 month period) shown below: Figure 1: Mean IOP during the study Cataracts and Cataract Surgery At baseline, 243 of the 324 OZURDEX ® subjects were phakic; 230 of 328 sham-controlled subjects were phakic. The incidence of cataract development in patients who had a phakic study eye was higher in the OZURDEX ® group (68%) compared with Sham (21%). The median time of cataract being reported as an adverse event was approximately 15 months in the OZURDEX ® group and 12 months in the Sham group. Among these patients, 61% of OZURDEX ® subjects vs. 8% of sham-controlled subjects underwent cataract surgery, generally between Month 18 and Month 39 (Median Month 21 for OZURDEX ® group and 20 for Sham) of the studies. 6.2 Postmarketing Experience The following reactions have been identified during post-marketing use of OZURDEX ® in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to OZURDEX ®, or a combination of these factors, include: complication of device insertion (implant misplacement), device dislocation with or without corneal edema, endophthalmitis, hypotony of the eye (associated with vitreous leakage due to injection), and retinal detachment.

Usage information

Dosing and administration
2 DOSAGE AND ADMINISTRATION For ophthalmic intravitreal injection. (2.1) The intravitreal injection procedure should be carried out under controlled aseptic conditions. (2.2) Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. (2.2) 2.1 General Dosing Information For ophthalmic intravitreal injection. 2.2 Administration The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide applied to the periocular skin, eyelid and ocular surface are recommended to be given prior to the injection. Remove the foil pouch from the carton and examine for damage. Then, open the foil pouch over a sterile field and gently drop the applicator on a sterile tray. Carefully remove the cap from the applicator. Hold the applicator in one hand and pull the safety tab straight off the applicator. Do not twist or flex the tab. The long axis of the applicator should be held parallel to the limbus, and the sclera should be engaged at an oblique angle with the bevel of the needle up (away from the sclera) to create a shelved scleral path. The tip of the needle is advanced within the sclera for about 1 mm (parallel to the limbus), then re-directed toward the center of the eye and advanced until penetration of the sclera is completed and the vitreous cavity is entered. The needle should not be advanced past the point where the sleeve touches the conjunctiva. Slowly depress the actuator button until an audible click is noted. Before withdrawing the applicator from the eye, make sure that the actuator button is fully depressed and has locked flush with the applicator surface. Remove the needle in the same direction as used to enter the vitreous. Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay. Each applicator can only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new applicator must be used, and the sterile field, syringe, gloves, drapes, and eyelid speculum should be changed before OZURDEX ® is administered to the other eye.
Use in special populations
8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with OZURDEX ® in pregnant women. Topical ocular administration of dexamethasone in mice and rabbits during the period of organogenesis produced cleft palate and embryofetal death in mice, and malformations of the abdominal wall/intestines and kidneys in rabbits at doses 5 and 4 times higher than the recommended human ophthalmic dose (RHOD) of OZURDEX® (0.7 milligrams dexamethasone), respectively. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Topical ocular administration of 0.15% dexamethasone (0.75 mg/kg/day) on gestational days 10 to 13 produced embryofetal lethality and a high incidence of cleft palate in mice. A dose of 0.75 mg/kg/day in the mouse is approximately 5 times an OZURDEX ® injection in humans (0.7 mg dexamethasone) on a mg/m2 basis. In rabbits, topical ocular administration of 0.1% dexamethasone throughout organogenesis (0.20 mg/kg/day, on gestational day 6 followed by 0.13 mg/kg/day on gestational days 7-18) produced intestinal anomalies, intestinal aplasia, gastroschisis and hypoplastic kidneys. A dose of 0.13 mg/kg/day in the rabbit is approximately 4 times an OZURDEX ® injection in humans (0.7 mg dexamethasone) on a mg/m2 basis. A no-observed-adverse-effect-level (NOAEL) was not identified in the mouse or rabbits studies. 8. 2 Lactation Risk Summary Systemically administered corticosteroids are present in human milk and can suppress growth and interfere with endogenous corticosteroid production or cause other unwanted effects. There is no information regarding the presence of dexamethasone in human milk, the effects on the breastfed infants, or the effects on milk producton to inform risk of OZURDEX® to an infant during lactation. The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for OZURDEX ® and any potential adverse effects on the breastfed child from OZURDEX ® . 8.4 Pediatric Use Safety and effectiveness of OZURDEX ® in pediatric patients have not been established. 8.5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.

More information

Category Value
Authorisation number NDA022315
Agency product number 7S5I7G3JQL
Orphan designation No
Product NDC 0023-3348
Date Last Revised 15-05-2018
Type HUMAN PRESCRIPTION DRUG
RXCUI 854177
Marketing authorisation holder Allergan, Inc.